Sanofi (SANp)
Euronext Paris • Healthcare
July 27, 2026 at 10:37 UTC
About Sanofi
Sanofi is a healthcare company listed on Euronext Paris under SAN.PA that researches, develops, manufactures, and commercializes therapeutic solutions across prescription medicines, vaccines, and consumer health products. In FY2025, the group generated EUR 43.6 billion in revenue through a business that spans the United States, Europe, and other international markets.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Sanofi's Technical Indicators Summary
Sanp is trading near 76.03 with a neutral set of indicators: momentum measures are mixed while MACD shows modest positive bias and RSI sits around the midpoint, implying little directional conviction. ADX indicates a weak trend and short-term moving averages lie very close to the price while the 200-day average is notably higher, signaling longer-term resistance. Volatility is moderate with ATR near 1.7 and on-balance volume is weak, suggesting limited buying pressure. The classic pivot is almost on the market, reinforcing the indecision. Technical takeaway: Neutral.
| Indicator | Value |
|---|---|
RSI (14) | 50.33 |
Stochastic %K (14, 3, 3) | 51.31 |
CCI (20) | -44.69 |
WPR (14) | -55.07 |
Momentum (10) | -0.20 |
MFI | 53.56 |
MACD Level (12, 26) | 0.36 |
Bollinger Bands | $73.92 - $77.99 |
ATR (14) | $1.68 (2.21%) |
ADX (14) | 12.52 |
OBV | 3,577,232 |
Classic Pivot Point | $76.18 |
Fibonacci Pivot Point | $76.18 |
Simple Moving Averages | $75.65 - $80.12(5 indicators) |
Exponential Moving Averages | $76.08 - $79.28(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
SANp kicked off the day with a gentle 0.68% gap higher, setting the open at 76.55 after yesterday’s 76.03. At the open, positioning in SANp comes ahead of results due in 3 days (30 July). SANp is buoyed by Sanofi's bioequivalence study for REZUROCK suspension, signaling potential product-driven upside before results.
Trading Volume
Below 10d avg (1.8M)
190.1K
vs S&P 500 Today
Outperforming Market
+0.92%
52-Week Position
Lower range
27.7%
Updated: July 27, 2026 at 09:37 UTC
Quote Summary
SANp Headlines
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Japan clears Dupixent for bullous pemphigoid
March 24, 2026
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
March 15, 2026
Azoria ETFs shut, Novartis India stake sold, tariff shock
February 20, 2026